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Gametocyte density and sex ratio can predict the proportion 
of mosquitoes that will become infected after feeding on blood 
of patients receiving nongametocytocidal drugs. Because pri-
maquine and methylene blue sterilize gametocytes before affect-
ing their density and sex ratio, mosquito feeding experiments 
are required to demonstrate their early transmission-blocking 
effects.
Keywords. malaria; infectiousness; anopheles; transmis-
sion; treatment.
Transmission of malaria depends on mature sexual stage par-
asites (gametocytes) in the peripheral blood. Blood-feeding 
Anopheles mosquitoes must ingest at least 1 male and 1 female 
gametocyte to become infected. The formation of Plasmodium 
oocysts on the mosquito midgut wall is commonly used as 
evidence for successful transmission. These oocysts enlarge 
over time to rupture and release sporozoites that render mos-
quitoes infectious. In the absence of treatment, infectivity of 
malaria-infected individuals can be reasonably well predicted 
by the density of male and female gametocytes in their periph-
eral blood [1]. Antimalarial drugs differ in their activity against 
gametocytes [2]. Artemisinins effectively clear asexual parasites 
and developing gametocytes but have limited efficacy against 
mature gametocytes [3–5] and therefore do not fully prevent 
transmission after treatment [4]. 
Primaquine (PQ) and methylene blue (MB) are potent 
gametocytocidal compounds. For these drugs, effects on trans-
missibility may occur before a measurable impact on total 
gametocyte density [6]. One plausible explanation for this early 
transmission blockade would be a preferential clearance of 
male or female gametocytes, resulting in a distorted, nonviable 
gametocyte sex ratio [7]. Gametocytocidal drugs may indeed 
exert different effects on male and female gametocytes [2, 8], 
with MB preferentially clearing male gametocytes [4] and indi-
cations that PQ may preferentially clear female gametocytes 
[4]. An alternative explanation for early transmission blockade 
would be a gametocyte-sterilizing effect, that is, a reduction in 
gametocyte infectivity in the absence of, or prior to, an effect on 
density. We recently presented a mathematical model to predict 
mosquito infection rates based on gametocyte density and sex 
ratio [1]. Here, we utilize this model to determine whether early 
transmission-blocking effects of PQ and MB can be explained 
by the effects these compounds have on gametocyte density or 
sex ratio or whether there is evidence for a sterilizing effect that 
precedes gametocyte clearance.
METHODS
We used data from a previously reported, single-blind, ran-
domized, controlled trial that received ethical approval from 
the University of Science, Techniques, and Technologies 
(Bamako, Mali), the University of California–San Francisco, 
and the London School of Hygiene & Tropical Medicine 
(United Kingdom) [4]. The trial compared sulfadoxine-pyri-
methamine and amodiaquine (SP/AQ) and dihydroartemisi-
nin-piperaquine (DP) as nongametocytocidal drugs with no 
established effects on mature gametocytes, with SP/AQ plus a 
single dose of 0·25 mg/kg PQ (SP/AQ-PQ) and DP plus 15 mg/kg 
MB per day for 3  days (DP-MB) as gametocytocidal drug 
combinations [4]. Following written informed consent (par-
ticipants aged ≥18  years) or parental consent (participants 
aged <18  years) with assent for children aged 12–17  years, 
asymptomatic microscopy-positive gametocyte carriers 
aged 5–50  years were recruited in Ouélessébougou, Mali. 
Infectivity of participants to mosquitoes (the percentage of 
mosquitoes that develop oocysts) was assessed by membrane 
feeding assay prior to treatment and on days 2 and 7 after 
initiation of treatment. Density of male and female gameto-
cytes was determined by quantitative reverse-transcription 
polymerase chain reaction assays that target female (Pfs25) 
and male (PfMGET) gametocyte transcripts with sex-spe-
cific trend lines [9]. Comparisons of gametocyte densities 
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were done using t tests on log-transformed values, giving 
estimates of the ratio of geometric mean (RGM) densities 
of male and female gametocytes between treatment groups. 
To make log-transformation possible, zeros were imputed to 
0.005 gametocytes per microliter (half the minimum detect-
ible concentration). Infectivity in DP-MB and SP/AQ-PQ 
arms was compared with that of nongametocytocidal drugs 
(DP or SP/AQ) using a previously published statistical model, 
controlling for male and female gametocyte density [1]. 
Because of low infectivity following DP-MB or SP/AQ-PQ, 
it was not possible to estimate the relative reduction in prob-
ability of transmission conditional upon gametocyte density 
(models failed to converge). To overcome this, the nonpara-
metric van Elteren’s test, an extension of the Wilcoxon rank 
sum test that compares groups in a stratified manner [10], 
was used. Because gametocyte density is a strong nonlinear 
determinant of infectivity, we compared infectivity between 
groups after stratifying in categories 1, 1 to <5, 5 to <20, 20 
to <50, 50 to <100, and ≥100 total gametocytes per microliter. 
Infectivity was then compared within different bins to test for 
differences between arms, accounting for gametocytemia.
RESULTS
The study was conducted from 27 June 2016 through 1 
November 2016. Samples from 80 participants were analyzed at 
enrollment and on day 2 and day 7 post-initiation of treatment. 
On day 2 there was no evidence that female gametocyte densities 
were lower following treatment with DP-MB (RGM with 95% 
confidence interval 0.37 [0.12, 1.13]; P  =  .079) or SP/AQ-PQ 
(RGM = 1.23 [0.39, 3.94]; P = .718) compared to nongametocy-
tocidal drugs (Figure 1A). Similarly, there was no evidence that 
male gametocyte densities were lower on day 2 following treat-
ment with DP-MB (RGM = 0.54 [0.26, 1.09]; P = .085) or SP/
AQ-PQ (RGM = 1.81 [0.95, 3.46]; P = .071) compared to non-
gametocytocidal drugs (Figure 1A). In contrast, treatment with 
DP-MB reduced day 7 densities of both female (RGM = 0.015 
[0.004, 0.053]; P < .001) and male gametocytes (RGM = 0.002 
[0.001, 0.007]; P < .001) and treatment with SP/AQ-PQ reduced 
day 7 densities of both female (RGM  =  0.003 [0.001, 0.010]; 
P < .001) and male gametocytes (RGM = 0.254 [0.082, 0.787]; 
P = .018) compared to nongametocytocidal drugs (Figure 1B).
In a model adjusted for male and female gametocyte 
density, there was no evidence that among nongametocy-
tocidal arms infectivity differed between baseline and day 
2 (risk ratio [RR] = 1.08 [0.57, 2.03]; P = .819; Figure 1C) 
and between baseline and day 7 (RR  =  1.51 [0.71, 3.32]; 
P = .288; Figure 1C). Infectivity at a given density was sim-
ilar for those on SP-AQ compared to DP (RR = 0.72 [0.36, 
1.43]; P  =  .345). Despite considerable overlap of gameto-
cyte densities in all arms, infectivity after DP-MB and SP/
AQ-PQ was substantially lower on day 2.  For those on 
nongametocytocidal drugs, 22/36 (61%) were infectious to 
mosquitoes on day 2 compared to 0/19 (0%) on DP-MB 
and 1/19 (5%) on SP/AQ-PQ, with strong evidence for 
lower infectivity after adjusting for gametocyte density 
(van Elteren’s test, P  <  .001). The reduction in infectiv-
ity on day 2 was thus not explained by gametocyte den-
sity (Figure 1D) or sex ratio (Figure 1A). Infectivity for 
gametocyte-positive individuals on MB and PQ remained 
lower on day 7, with 19/36 (53%) on nongametocytocidal 
drugs infectious to mosquitoes compared to 0/8 (0%) of 
those on MB and 0/11 (0%) of those on PQ (Figure 1D). 
There was less overlap in gametocyte densities between 
those on MB or PQ and those on gametocytocidal drugs. 
However, again there was evidence that infectivity was 
lower for those on gametocytocidal drugs after adjusting 
for gametocyte density (van Elteren’s test, P = .044).
DISCUSSION
We found that measures of mRNA gametocyte density do 
not correlate with infectivity shortly after treatment with 
gametocytocidal drugs. The major implication of this find-
ing is that studies that examine transmission-blocking 
effects of drugs and potentially vaccines require mosqui-
to-feeding assays to measure infectivity. Gametocytocidal 
drugs rapidly clear gametocytes, distort the gametocyte sex 
ratio [4, 11], and prevent onward transmission to mosqui-
toes [4, 6, 7]. Although it was previously reported that the 
transmission-blocking effect of PQ may precede its gameto-
cyte clearing effect [7], it has been unclear to what extent 
an early effect of sex ratio may contribute to this rapid pre-
vention of onward transmission [7]. For MB we previously 
hypothesized that its preferential clearance of male gameto-
cytes may (partially) explain its early transmission-blocking 
effects [4]. 
Here, we present evidence that gametocyte density and 
sex ratio are unaffected in the first 48 hours after initiation 
of treatment, despite a near complete prevention of onward 
transmission to mosquitoes. Nongametocytocidal drugs did 
not alter the shape of the associations between gametocyte 
density, sex ratio, and mosquito infection prevalence; gameto-
cytes appeared equally infectious before and after treatment. 
In contrast, gametocyte density and sex ratio no longer 
explained transmission after treatment with DP-MB or SP/
AQ-PQ; gametocytes persisted with sex ratios similar to those 
before treatment, but mosquito infections were nearly com-
pletely prevented. 
The mechanism that underlies the early sterilizing effect de-
spite continued presence of gametocyte mRNA transcripts is 
unclear. While mRNA is unlikely to survive in free-floating 
form and, also by microscopy, gametocyte densities remain 
unaffected shortly after treatment [6], it is possible that mRNA 
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persists in red blood cells with parasites that are damaged by 
treatment. Upon reaching maturity, gametocytes complete 
their preparations for onward development and maintain cell 
cycle arrest until triggered to differentiate into gametes in the 
mosquito. Therefore, metabolic activity of mature gametocytes 
is likely reduced to “housekeeping” functions such as ATP pro-
duction and general redox activity. Antimalarials that cause 
generalized cellular damage such as oxidative stress induced 
by MB inhibition of glutathione reductase [12] may manifest 
an initial transmission-blocking effect that is only apparent 
when gametocytes re-engage the complex cellular processes re-
quired for successful gametogenesis. PQ is similarly postulated 
to operate through reactive metabolites that cause nonspecific 
damage to gametocytes [13]. 
The molecular mechanisms that underlie the apparent 
male-biased clearance of gametocytes after MB treatment and 
female-biased clearance after PQ treatment are currently un-
clear; however, they likely reflect the sexual dimorphism of 
gametocyte proteomes. Our findings thus provide evidence 
for an early sterilizing effect of MB and PQ. Molecular tools to 
quantify male and female gametocytes cannot replace mosqui-
to-feeding experiments to assess transmission-blocking proper-
ties of antimalarials.
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Figure 1. Associations between gametocyte density, sex ratio, treatment, and the proportion of mosquitoes that developed oocysts (became infected). The association 
between male and female gametocyte density is presented for day 2 (A) and day 7 (B) post-initiation of treatment. The association between female gametocyte density and 
the proportion of infected mosquitoes is presented for individuals who received nongametocytocidal drugs (C) and gametocytocidal drugs (D). In all panels, green symbols 
represent observations following dihydroartemisinin-piperaquine (DP); orange, sulfadoxine-pyrimethamine and amodiaquine (SP/AQ); maroon, DP-methylene blue; and blue, 
SP/AQ-primaquine. Crosses represent feeding outcomes from experiments conducted on day 2 post-initiation of treatment and triangles represent feeding outcomes from 
experiments conducted on day 7 post-initiation of treatment. (C and D) The proportion of mosquitoes that developed oocysts prior to treatment plotted in light gray circles for 
all treatment arms for illustrative purposes; the black line indicates the shape of the best fit relationship between female gametocyte density and infectivity in the absence 
of malaria treatment as previously defined [1].
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